EICHORCondition: Smoldering Multiple Myeloma · Sponsor: Janssen Research & Development, LLC
Sponsor, CRO or site team? See where this study is running → — listed sites, countries and recruiting context. Everything below is written for patients and caregivers.
The primary objective of this study is to determine whether treatment with daratumumab administered subcutaneously (SC) prolongs progression-free survival (PFS) compared with active monitoring in participants with high-risk smoldering multiple myeloma (SMM).
This description comes directly from the study's public registry record.
No contact information is available for this study as per the public registry record.
Always discuss trial participation with your own doctor first.
| Arizona Oncology Associates, PC - HAL | Phoenix, Arizona, United States | — |
| Innovative Clinical Research Inc | Whittier, California, United States | — |
| Miami Cancer Institute | Miami, Florida, United States | — |
| Emory University | Atlanta, Georgia, United States | — |
| University of Iowa Hospitals and Clinics | Iowa City, Iowa, United States | — |
| East Jefferson General Hospital | Metairie, Louisiana, United States | — |
| Dana Farber Cancer Institute | Boston, Massachusetts, United States | — |
| University of Michigan Comprehensive Cancer Center | Ann Arbor, Michigan, United States | — |
| Mayo Clinic | Rochester, Minnesota, United States | — |
| Washington University | St Louis, Missouri, United States | — |
| VA Southern Nevada Healthcare | North Las Vegas, Nevada, United States | — |
| New York Oncology Hematology | Albany, New York, United States | — |
+ 151 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT03301220